Trial watch: Dendritic cell-based anticancer immunotherapy.

Garg, Abhishek D; Vara Perez, Monica; Schaaf, Marco; Agostinis, Patrizia; Zitvogel, Laurence; Kroemer, Guido; Galluzzi, Lorenzo

Garg, Abhishek D; Vara Perez, Monica; Schaaf, Marco; Agostinis, Patrizia; Zitvogel, Laurence; Kroemer, Guido; Galluzzi, Lorenzo.

Afiliação

Garg AD; Cell Death Research & Therapy (CDRT) Lab, Department of Cellular & Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium.
Vara Perez M; Cell Death Research & Therapy (CDRT) Lab, Department of Cellular & Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium.
Schaaf M; Cell Death Research & Therapy (CDRT) Lab, Department of Cellular & Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium.
Agostinis P; Cell Death Research & Therapy (CDRT) Lab, Department of Cellular & Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium.
Zitvogel L; Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Kroemer G; INSERM, U1015, Villejuif, France.
Galluzzi L; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France.

Oncoimmunology ; 6(7): e1328341, 2017.

Article em En | MEDLINE | ID: mdl-28811970

Palavras-chave

Antigen cross-presentation; DAMPs; TLR signaling; immune-checkpoint blockers; plasmacytoid dendritic cells; tumor-infiltrating lymphocytes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Idioma: En Revista: Oncoimmunology Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Bélgica

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google